Canaccord analyst John Newman upgraded Regeneron to Buy from Hold with a price target of $992, up from $720.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron Stock (NASDAQ:REGN): Analysts are Bullish Post FDA Approval
- Regeneron price target raised to $830 from $820 at RBC Capital
- Regeneron price target raised to $985 from $960 at BMO Capital
- Regeneron price target raised to $980 from $875 at Wells Fargo
- Regeneron price target raised to $1,050 from $950 at Oppenheimer